HRP20141170T1 - Monoklonska antitijela koja se vežu za b7h6 i njihove uporabe - Google Patents

Monoklonska antitijela koja se vežu za b7h6 i njihove uporabe Download PDF

Info

Publication number
HRP20141170T1
HRP20141170T1 HRP20141170AT HRP20141170T HRP20141170T1 HR P20141170 T1 HRP20141170 T1 HR P20141170T1 HR P20141170A T HRP20141170A T HR P20141170AT HR P20141170 T HRP20141170 T HR P20141170T HR P20141170 T1 HRP20141170 T1 HR P20141170T1
Authority
HR
Croatia
Prior art keywords
antibody
cell
human
drug conjugate
expressing
Prior art date
Application number
HRP20141170AT
Other languages
English (en)
Croatian (hr)
Inventor
Michel Pierres
Eric Vivier
Myriam Baratin
Original Assignee
Institut National de la Santé et de la Recherche Médicale
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43827827&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20141170(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Institut National de la Santé et de la Recherche Médicale filed Critical Institut National de la Santé et de la Recherche Médicale
Publication of HRP20141170T1 publication Critical patent/HRP20141170T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HRP20141170AT 2009-12-09 2010-12-08 Monoklonska antitijela koja se vežu za b7h6 i njihove uporabe HRP20141170T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28501809P 2009-12-09 2009-12-09
PCT/IB2010/003411 WO2011070443A1 (en) 2009-12-09 2010-12-08 Monoclonal antibodies that bind b7h6 and uses thereof
EP10813116.0A EP2510011B2 (en) 2009-12-09 2010-12-08 Monoclonal antibodies that bind b7h6 and uses thereof

Publications (1)

Publication Number Publication Date
HRP20141170T1 true HRP20141170T1 (hr) 2015-01-30

Family

ID=43827827

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20141170AT HRP20141170T1 (hr) 2009-12-09 2010-12-08 Monoklonska antitijela koja se vežu za b7h6 i njihove uporabe

Country Status (18)

Country Link
US (2) US8822652B2 (https=)
EP (1) EP2510011B2 (https=)
JP (2) JP2013513380A (https=)
CN (2) CN104926942B (https=)
BR (1) BR112012013975B8 (https=)
CA (1) CA2783740C (https=)
DK (1) DK2510011T3 (https=)
EA (1) EA024629B1 (https=)
ES (1) ES2523472T3 (https=)
HR (1) HRP20141170T1 (https=)
IN (1) IN2012DN04908A (https=)
MX (1) MX2012006443A (https=)
PL (1) PL2510011T3 (https=)
PT (1) PT2510011E (https=)
RS (1) RS53667B1 (https=)
SI (1) SI2510011T1 (https=)
SM (1) SMT201400184B (https=)
WO (1) WO2011070443A1 (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12492376B2 (en) 2009-10-29 2025-12-09 The Trustees Of Dartmouth College T-cell receptor-deficient T cell compositions
WO2011059836A2 (en) 2009-10-29 2011-05-19 Trustees Of Dartmouth College T cell receptor-deficient t cell compositions
US9273283B2 (en) 2009-10-29 2016-03-01 The Trustees Of Dartmouth College Method of producing T cell receptor-deficient T cells expressing a chimeric receptor
EP2510011B2 (en) 2009-12-09 2021-03-31 Institut National de la Santé et de la Recherche Médicale Monoclonal antibodies that bind b7h6 and uses thereof
US9833476B2 (en) 2011-08-31 2017-12-05 The Trustees Of Dartmouth College NKP30 receptor targeted therapeutics
JP2014534165A (ja) * 2011-09-13 2014-12-18 ドイチェス クレブスフォルシュンクスツェントルム Ｂ７−ｈ６ポリペプチドに対するｂ７−ｈ６治療活性モノクローナル抗体
ES2719495T5 (en) 2012-05-07 2025-09-10 Dartmouth College Anti-b7-h6 antibody, fusion proteins, and methods of using the same
EP2711707A1 (en) 2012-09-21 2014-03-26 Institut Gustave Roussy Methods and kits for predicting the sensitivity of a subject to chemotherapy
WO2014044799A1 (en) * 2012-09-21 2014-03-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and kits for the diagnosing of inflammatory conditions involving detecting, identifying or assaying for soluble b7-h6 polypeptides
US11034767B2 (en) * 2016-04-15 2021-06-15 Trustees Of Dartmouth College High affinity B7-H6 antibodies and antibody fragments
WO2017214433A1 (en) * 2016-06-09 2017-12-14 Seattle Genetics, Inc. Combinations of pbd-based antibody drug conjugates with flt3 inhibitors
JP7500005B2 (ja) * 2017-11-16 2024-06-17 ヴィスカ・バイオ・インコーポレイテッド リソソーム誘発性免疫原性細胞死のシステムおよび方法
EP3737692A4 (en) 2018-01-09 2021-09-29 Elstar Therapeutics, Inc. CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES
US12152073B2 (en) 2018-03-14 2024-11-26 Marengo Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
EP3818083A2 (en) 2018-07-03 2021-05-12 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
JP7710373B2 (ja) 2019-02-21 2025-07-18 マレンゴ・セラピューティクス，インコーポレーテッド Ｔ細胞関連のがん細胞に結合する多機能性分子およびその使用
AU2020224681A1 (en) 2019-02-21 2021-09-16 Marengo Therapeutics, Inc. Antibody molecules that bind to NKp30 and uses thereof
CN116234829A (zh) 2020-01-03 2023-06-06 马伦戈治疗公司 抗tcr抗体分子及其用途
WO2021143858A1 (en) * 2020-01-17 2021-07-22 Beigene, Ltd. ANTI-NKp30 ANTIBODIES AND METHODS OF USE
MX2023011310A (es) 2021-03-26 2023-10-05 Innate Pharma Anclajes de citocina para proteinas de celulas nk de union a nkp46.
BR112023025331A2 (pt) 2021-06-09 2024-02-27 Innate Pharma Proteína multiespecífica, composição farmacêutica, célula recombinante, ácido nucleico ou conjunto de ácidos nucleicos, uso de uma proteína ou composição, métodos ou uso
WO2022258691A1 (en) 2021-06-09 2022-12-15 Innate Pharma Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a
WO2022258678A1 (en) 2021-06-09 2022-12-15 Innate Pharma Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a
CN114395044B (zh) * 2021-12-07 2023-12-29 合肥天港免疫药物有限公司 重组抗体及其应用
CN114395043B (zh) * 2021-12-07 2023-07-11 合肥天港免疫药物有限公司 Ncr3lg1抗体及其应用
CN114395045B (zh) * 2021-12-07 2023-06-09 合肥天港免疫药物有限公司 B7h6抗体及其应用
CN114395047B (zh) * 2021-12-07 2023-11-07 合肥天港免疫药物有限公司 双特异性抗体及其应用
CN114634574B (zh) * 2022-04-18 2022-12-20 先进生物(苏州)有限公司 抗B7H6的scFv抗体、其编码基因及其应用
WO2024005422A1 (ko) * 2022-06-29 2024-01-04 고려대학교 산학협력단 Nkp30 결합력이 향상된 b7-h6 변이체
EP4619509A1 (en) * 2022-11-16 2025-09-24 Deutsches Krebsforschungszentrum T cell-nk cell interaction inhibitors for use in disease treatment
WO2024208818A1 (en) 2023-04-04 2024-10-10 Innate Pharma Modular chimeric antigen receptor

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4486414A (en) 1983-03-21 1984-12-04 Arizona Board Of Reagents Dolastatins A and B cell growth inhibitory substances
US4883662A (en) 1984-04-10 1989-11-28 Clinical Biotechnologies, Inc. Method of increasing natural killer cell population of cancer patients
US4880935A (en) 1986-07-11 1989-11-14 Icrf (Patents) Limited Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4816444A (en) 1987-07-10 1989-03-28 Arizona Board Of Regents, Arizona State University Cell growth inhibitory substance
IL106992A (en) 1988-02-11 1994-06-24 Bristol Myers Squibb Co Acylhydrazone derivatives of anthracycline and methods for their preparation
ATE120454T1 (de) 1988-06-14 1995-04-15 Cetus Oncology Corp Kupplungsmittel und sterisch gehinderte, mit disulfid gebundene konjugate daraus.
US5082833A (en) 1988-06-30 1992-01-21 Shamsuddin Abulkalam M Reduction of cell proliferation and enhancement of nk-cell activity
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5076973A (en) 1988-10-24 1991-12-31 Arizona Board Of Regents Synthesis of dolastatin 3
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US4978744A (en) 1989-01-27 1990-12-18 Arizona Board Of Regents Synthesis of dolastatin 10
US4879278A (en) 1989-05-16 1989-11-07 Arizona Board Of Regents Isolation and structural elucidation of the cytostatic linear depsipeptide dolastatin 15
US4986988A (en) 1989-05-18 1991-01-22 Arizona Board Of Regents Isolation and structural elucidation of the cytostatic linear depsipeptides dolastatin 13 and dehydrodolastatin 13
US5138036A (en) 1989-11-13 1992-08-11 Arizona Board Of Regents Acting On Behalf Of Arizona State University Isolation and structural elucidation of the cytostatic cyclodepsipeptide dolastatin 14
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
CA2405246A1 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with alterred binding properties
JP3202999B2 (ja) 1991-01-31 2001-08-27 協和醗酵工業株式会社 肝移行性リポソーム製剤
ES2341666T3 (es) 1991-12-02 2010-06-24 Medimmune Limited Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US6034065A (en) 1992-12-03 2000-03-07 Arizona Board Of Regents Elucidation and synthesis of antineoplastic tetrapeptide phenethylamides of dolastatin 10
US5410024A (en) 1993-01-21 1995-04-25 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
US5556623A (en) 1993-03-30 1996-09-17 Eli Lilly And Company Antibody-drug conjugates
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
US5504191A (en) 1994-08-01 1996-04-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide methyl esters
US5530097A (en) 1994-08-01 1996-06-25 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory peptide amides
US5521284A (en) 1994-08-01 1996-05-28 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide amides and esters
US5554725A (en) 1994-09-14 1996-09-10 Arizona Board Of Regents Acting On Behalf Of Arizona State University Synthesis of dolastatin 15
US5599902A (en) 1994-11-10 1997-02-04 Arizona Board Of Regents Acting On Behalf Of Arizona State University Cancer inhibitory peptides
US5663149A (en) 1994-12-13 1997-09-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
ATE234635T1 (de) 1995-12-22 2003-04-15 Bristol Myers Squibb Co Verzweigte hydrazongruppen enthaltende kuppler
US6130237A (en) 1996-09-12 2000-10-10 Cancer Research Campaign Technology Limited Condensed N-aclyindoles as antitumor agents
DE69832158T2 (de) 1997-02-25 2006-08-10 Arizona Board Of Regents, Tempe Isolierung und strukturelle aufklärung der kryostatischen linearen und cyclo-depsipeptide dolastatin 16, dolastatin 17, und dolastatin 18
US6323315B1 (en) 1999-09-10 2001-11-27 Basf Aktiengesellschaft Dolastatin peptides
AU2769101A (en) * 2000-01-07 2001-07-24 Millennium Pharmaceuticals, Inc. Novel genes encoding proteins having prognostic, diagnostic, preventive, therapeutic, and other uses
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US20030083263A1 (en) 2001-04-30 2003-05-01 Svetlana Doronina Pentapeptide compounds and uses related thereto
SI1545613T1 (sl) 2002-07-31 2011-11-30 Seattle Genetics Inc Avristatinski konjugati in njihova uporaba za zdravljenje raka avtoimunske bolezni ali infekcijskebolezni
WO2004022594A2 (en) * 2002-09-06 2004-03-18 Cytos Biotechnology Ag Immune modulatory compounds and methods
JP2008540569A (ja) * 2005-05-12 2008-11-20 ザイモジェネティクス， インコーポレイテッド 免疫系を調整するためにＢ７ファミリーメンバーであるｐＮＫｐ３０を使用する方法
EP2144930A1 (en) 2007-04-18 2010-01-20 ZymoGenetics, Inc. Single chain fc, methods of making and methods of treatment
KR101662622B1 (ko) 2007-10-04 2016-10-05 지모제넥틱스, 인코포레이티드 Ｂ7 패밀리 구성원 ｚＢ7Ｈ6 및 관련된 조성물 및 방법
EP2510011B2 (en) 2009-12-09 2021-03-31 Institut National de la Santé et de la Recherche Médicale Monoclonal antibodies that bind b7h6 and uses thereof

Also Published As

Publication number Publication date
US8822652B2 (en) 2014-09-02
JP2017031147A (ja) 2017-02-09
EA201270654A1 (ru) 2013-02-28
BR112012013975B1 (pt) 2021-01-12
CN104926942B (zh) 2018-09-14
SI2510011T1 (sl) 2014-12-31
CN102741290B (zh) 2015-04-22
US20130004432A1 (en) 2013-01-03
JP6212181B2 (ja) 2017-10-11
PT2510011E (pt) 2014-12-12
PL2510011T3 (pl) 2015-02-27
EP2510011A1 (en) 2012-10-17
US20150056214A1 (en) 2015-02-26
BR112012013975A2 (pt) 2017-01-10
US9663577B2 (en) 2017-05-30
DK2510011T3 (en) 2014-12-01
CN102741290A (zh) 2012-10-17
JP2013513380A (ja) 2013-04-22
RS53667B1 (sr) 2015-04-30
BR112012013975B8 (pt) 2021-05-25
ES2523472T3 (es) 2014-11-26
CA2783740A1 (en) 2011-06-16
CN104926942A (zh) 2015-09-23
WO2011070443A1 (en) 2011-06-16
EP2510011B2 (en) 2021-03-31
EP2510011B1 (en) 2014-09-17
CA2783740C (en) 2020-03-10
EA024629B1 (ru) 2016-10-31
SMT201400184B (it) 2015-01-15
IN2012DN04908A (https=) 2015-09-25
MX2012006443A (es) 2012-06-28

Similar Documents

Publication Publication Date Title
HRP20141170T1 (hr) Monoklonska antitijela koja se vežu za b7h6 i njihove uporabe
JP2013513380A5 (https=)
KR102022734B1 (ko) 신규 조절제 및 용법
US20240199738A1 (en) Monoclonal antibodies and conjugates against prostaglandin f2 receptor inhibitor and uses thereof
AU2011360938B2 (en) Novel modulators and methods of use
AU2011293127B2 (en) Notum protein modulators and methods of use
ES2871816T3 (es) Anticuerpos anti-LAMP1 y conjugados anticuerpo-fármaco, y usos de los mismos
WO2016118090A1 (en) Cancer specific antigen-binding proteins
CA2810016A1 (en) Novel modulators and methods of use
WO2013126746A2 (en) Novel modulators and methods of use
JP2016538318A (ja) 新規ｓｅｚ６モジュレーターおよび使用方法
US11353458B2 (en) Prognostic method
TW201136608A (en) Novel humanized anti CXCR4 antibodies for the treatment of cancer
US20250257126A1 (en) Therapeutic antibodies
US20260078179A1 (en) Cdh17 antibodies and uses thereof
NZ615285B2 (en) Novel modulators and methods of use